Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Autologous mesenchymal stromal cells embedded in tricalcium phosphate for posterolateral spinal fusion: results of a prospective phase I/II clinical trial with long-term follow-up.

Blanco JF, Villarón EM, Pescador D, da Casa C, Gómez V, Redondo AM, López-Villar O, López-Parra M, Muntión S, Sánchez-Guijo F.

Stem Cell Res Ther. 2019 Feb 22;10(1):63. doi: 10.1186/s13287-019-1166-4.

2.

SHP1 and SHP2 inhibition enhances the pro-differentiative effect of phorbol esters: an alternative approach against acute myeloid leukemia.

Pérez-Fernández A, López-Ruano G, Prieto-Bermejo R, Ijurko C, Díez-Campelo M, Sánchez-Guijo F, Hernández-Hernández Á.

J Exp Clin Cancer Res. 2019 Feb 14;38(1):80. doi: 10.1186/s13046-019-1097-z.

3.

Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD.

Martínez-Carrasco R, Sánchez-Abarca LI, Nieto-Gómez C, García EM, Sánchez-Guijo F, Argüeso P, Aijón J, Hernández-Galilea E, Velasco A.

Ocul Surf. 2019 Jan 7. pii: S1542-0124(18)30382-3. doi: 10.1016/j.jtos.2019.01.001. [Epub ahead of print]

PMID:
30630121
4.

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.

Hernández-Boluda JC, Pereira A, Pastor-Galán I, Alvarez-Larrán A, Savchuk A, Puerta JM, Sánchez-Pina JM, Collado R, Díaz-González A, Angona A, Sagüés M, García-Gutiérrez V, Boqué C, Osorio S, Vallansot R, Palomera L, Mendizábal A, Casado LF, Pérez-Encinas M, Pérez-López R, Ferrer-Marín F, Sánchez-Guijo F, García C, Heras NL, López-Lorenzo JL, Cervantes F, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC).

Blood Cancer J. 2018 Dec 2;8(10):91. doi: 10.1038/s41408-018-0125-0.

5.

Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation.

Rivera D, Bastida JM, Lopez-Corral L, Sanchez-Guijo F, Cabrero M, Martin A, Perez E, Lopez-Parra M, Avendaño A, Veiga A, Baile M, Arratibel N, Carrillo J, Vazquez L, Caballero MD, Gonzalez-Porras JR.

Bone Marrow Transplant. 2018 Oct 24. doi: 10.1038/s41409-018-0368-1. [Epub ahead of print] No abstract available.

PMID:
30356164
6.

Human Bone Marrow Mesenchymal Stromal Cells Promote Bone Regeneration in a Xenogeneic Rabbit Model: A Preclinical Study.

Blanco JF, García-Briñon J, Benito-Garzón L, Pescador D, Muntión S, Sánchez-Guijo F.

Stem Cells Int. 2018 Jul 5;2018:7089484. doi: 10.1155/2018/7089484. eCollection 2018.

7.

Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model.

Thielen FW, Blommestein HM, Oosten LEM, Calkoen FG, Lankester AC, Zwaginga JJ, Le Blanc K, Redondo A, Sánchez-Guijo F, Algeri M, Locatelli F, Fibbe WE, Uyl-de Groot CA.

Eur J Haematol. 2018 Aug 6. doi: 10.1111/ejh.13158. [Epub ahead of print]

PMID:
30084111
8.

Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II).

Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Moltó F, Núñez-Córdoba JM, López-Elío S, Andreu E, Sánchez-Guijo F, Aquerreta JD, Bondía JM, Valentí-Azcárate A, Del Consuelo Del Cañizo M, Villarón EM, Valentí-Nin JR, Prósper F.

J Transl Med. 2018 Jul 31;16(1):213. doi: 10.1186/s12967-018-1591-7.

9.

Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation.

Trento C, Bernardo ME, Nagler A, Kuçi S, Bornhäuser M, Köhl U, Strunk D, Galleu A, Sanchez-Guijo F, Gaipa G, Introna M, Bukauskas A, Le Blanc K, Apperley J, Roelofs H, Van Campenhout A, Beguin Y, Kuball J, Lazzari L, Avanzini MA, Fibbe W, Chabannon C, Bonini C, Dazzi F.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2365-2370. doi: 10.1016/j.bbmt.2018.07.015. Epub 2018 Jul 20.

10.

Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?

Osorio S, Escudero-Vilaplana V, Gómez-Centurión I, Pérez-López R, Ayala R, Vall-Llovera F, García-Gutierrez V, Gómez Casares MT, González San Miguel JD, Hernández-Rivas JÁ, Sánchez-Guijo F, Martínez-García AB, Villalón L, Conesa-García V, Rodriguez A, Casado F, Garcia-Gonzalez X, Sáez Perdomo MN, Baños Ú, Steegmann JL; CML Spanish Group (GELMC).

Ann Hematol. 2018 Nov;97(11):2089-2098. doi: 10.1007/s00277-018-3413-7. Epub 2018 Jun 28.

PMID:
29955943
11.

Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger's disease).

Martin-Rufino JD, Lozano FS, Redondo AM, Villaron EM, Rueda R, Fernandez-Samos R, Sanchez-Guijo F.

Stem Cell Res Ther. 2018 May 30;9(1):150. doi: 10.1186/s13287-018-0901-6.

12.

Mesenchymal Stromal Cell Irradiation Interferes with the Adipogenic/Osteogenic Differentiation Balance and Improves Their Hematopoietic-Supporting Ability.

Preciado S, Muntión S, Rico A, Pérez-Romasanta LA, Ramos TL, Ortega R, Borrajo J, Corchete LA, Rodríguez C, Díez-Campelo M, Sánchez-Abarca LI, Del Cañizo MC, Sánchez-Guijo F.

Biol Blood Marrow Transplant. 2018 Mar;24(3):443-451. doi: 10.1016/j.bbmt.2017.11.007. Epub 2017 Nov 16.

13.

Biocompatibility of two model elastin-like recombinamer-based hydrogels formed through physical or chemical cross-linking for various applications in tissue engineering and regenerative medicine.

Ibáñez-Fonseca A, Ramos TL, González de Torre I, Sánchez-Abarca LI, Muntión S, Arias FJ, Del Cañizo MC, Alonso M, Sánchez-Guijo F, Rodríguez-Cabello JC.

J Tissue Eng Regen Med. 2018 Mar;12(3):e1450-e1460. doi: 10.1002/term.2562. Epub 2017 Nov 26.

PMID:
28865091
14.

Mesenchymal stromal cells (MSC) from JAK2+ myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesis.

Ramos TL, Sánchez-Abarca LI, Rosón-Burgo B, Redondo A, Rico A, Preciado S, Ortega R, Rodríguez C, Muntión S, Hernández-Hernández Á, De Las Rivas J, González M, González Porras JR, Del Cañizo C, Sánchez-Guijo F.

PLoS One. 2017 Aug 10;12(8):e0182470. doi: 10.1371/journal.pone.0182470. eCollection 2017.

15.

Regeneration of hyaline cartilage promoted by xenogeneic mesenchymal stromal cells embedded within elastin-like recombinamer-based bioactive hydrogels.

Pescador D, Ibáñez-Fonseca A, Sánchez-Guijo F, Briñón JG, Arias FJ, Muntión S, Hernández C, Girotti A, Alonso M, Del Cañizo MC, Rodríguez-Cabello JC, Blanco JF.

J Mater Sci Mater Med. 2017 Aug;28(8):115. doi: 10.1007/s10856-017-5928-1. Epub 2017 Jun 24.

PMID:
28647792
16.

HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?

Ramos TL, Sánchez-Abarca LI, Redondo A, Hernández-Hernández Á, Almeida AM, Puig N, Rodríguez C, Ortega R, Preciado S, Rico A, Muntión S, Porras JRG, Del Cañizo C, Sánchez-Guijo F.

Oncotarget. 2017 Apr 25;8(17):28187-28202. doi: 10.18632/oncotarget.15969.

17.

Insights into the human mesenchymal stromal/stem cell identity through integrative transcriptomic profiling.

Roson-Burgo B, Sanchez-Guijo F, Del Cañizo C, De Las Rivas J.

BMC Genomics. 2016 Nov 21;17(1):944.

18.

Assessment of dry eye in a GVHD murine model: Approximation through tear osmolarity measurement.

Martínez-Carrasco R, Sánchez-Abarca LI, Nieto-Gómez C, García EM, Ramos TL, Velasco A, Sánchez-Guijo F, Aijón J, Hernández-Galilea E.

Exp Eye Res. 2017 Jan;154:64-69. doi: 10.1016/j.exer.2016.11.004. Epub 2016 Nov 3.

PMID:
27818317
19.

GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study.

Parody R, López-Corral L, Lopez-Godino O, Martinez C, Martino R, Solano C, Barba P, Caballero D, García-Cadenas I, Piñana JL, Marquez-Malaver FJ, Vazquez L, Esquirol A, Boluda JC, Sanchez-Guijo F, Pérez-Simon JA.

Bone Marrow Transplant. 2016 Nov;51(11):1524-1526. doi: 10.1038/bmt.2016.163. Epub 2016 Jun 13. No abstract available.

PMID:
27295268
20.

Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial.

Caballero-Velázquez T, Montero I, Sánchez-Guijo F, Parody R, Saldaña R, Valcarcel D, López-Godino O, Ferra I Coll C, Cuesta M, Carrillo-Vico A, Sánchez-Abarca LI, López-Corral L, Márquez-Malaver FJ, Pérez-Simón JA; GETH (Grupo Español de Trasplante Hematopoyético).

Clin Cancer Res. 2016 Dec 1;22(23):5673-5681. Epub 2016 Jun 29.

21.

Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.

Cervantes F, Correa JG, Pérez I, García-Gutiérrez V, Redondo S, Colomer D, Jiménez-Velasco A, Steegmann JL, Sánchez-Guijo F, Ferrer-Marín F, Pereira A, Osorio S; CML Spanish Group (GELMC).

Ann Hematol. 2017 Jan;96(1):81-85. doi: 10.1007/s00277-016-2839-z. Epub 2016 Oct 8.

PMID:
27717993
22.

Comparative analysis of the immunomodulatory capacities of human bone marrow- and adipose tissue-derived mesenchymal stromal cells from the same donor.

Valencia J, Blanco B, Yáñez R, Vázquez M, Herrero Sánchez C, Fernández-García M, Rodríguez Serrano C, Pescador D, Blanco JF, Hernando-Rodríguez M, Sánchez-Guijo F, Lamana ML, Segovia JC, Vicente Á, Del Cañizo C, Zapata AG.

Cytotherapy. 2016 Oct;18(10):1297-311. doi: 10.1016/j.jcyt.2016.07.006.

PMID:
27637760
23.

Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II).

Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Moltó F, Nuñez-Córdoba JM, Sánchez-Echenique C, Bondía JM, Aquerreta JD, Andreu EJ, Ornilla E, Villarón EM, Valentí-Azcárate A, Sánchez-Guijo F, Del Cañizo MC, Valentí-Nin JR, Prósper F.

J Transl Med. 2016 Aug 26;14(1):246. doi: 10.1186/s12967-016-0998-2.

24.

Immunomodulatory effects of bone marrow versus adipose tissue-derived mesenchymal stromal cells on NK cells: implications in the transplantation setting.

Blanco B, Herrero-Sánchez MD, Rodríguez-Serrano C, García-Martínez ML, Blanco JF, Muntión S, García-Arranz M, Sánchez-Guijo F, Del Cañizo C.

Eur J Haematol. 2016 Dec;97(6):528-537. doi: 10.1111/ejh.12765. Epub 2016 Jun 1.

PMID:
27118602
25.

[Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting].

García-Gutiérrez V, Jiménez-Velasco A, Gómez-Casares MT, Sánchez-Guijo F, López-Sendón JL, Steegmann Olmedillas JL.

Med Clin (Barc). 2016 Jun 17;146(12):561.e1-8. doi: 10.1016/j.medcli.2016.02.022. Epub 2016 Apr 20. Spanish.

PMID:
27107729
26.

Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients.

Muntión S, Ramos TL, Diez-Campelo M, Rosón B, Sánchez-Abarca LI, Misiewicz-Krzeminska I, Preciado S, Sarasquete ME, de Las Rivas J, González M, Sánchez-Guijo F, Del Cañizo MC.

PLoS One. 2016 Feb 2;11(2):e0146722. doi: 10.1371/journal.pone.0146722. eCollection 2016.

27.

MSC surface markers (CD44, CD73, and CD90) can identify human MSC-derived extracellular vesicles by conventional flow cytometry.

L Ramos T, Sánchez-Abarca LI, Muntión S, Preciado S, Puig N, López-Ruano G, Hernández-Hernández Á, Redondo A, Ortega R, Rodríguez C, Sánchez-Guijo F, del Cañizo C.

Cell Commun Signal. 2016 Jan 12;14:2. doi: 10.1186/s12964-015-0124-8.

28.

PTPN13 and β-Catenin Regulate the Quiescence of Hematopoietic Stem Cells and Their Interaction with the Bone Marrow Niche.

López-Ruano G, Prieto-Bermejo R, Ramos TL, San-Segundo L, Sánchez-Abarca LI, Sánchez-Guijo F, Pérez-Simón JA, Sánchez-Yagüe J, Llanillo M, Hernández-Hernández Á.

Stem Cell Reports. 2015 Oct 13;5(4):516-31. doi: 10.1016/j.stemcr.2015.08.003. Epub 2015 Sep 3.

29.

Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles.

Ramos TL, Sánchez-Abarca LI, López-Ruano G, Muntión S, Preciado S, Hernández-Ruano M, Rosado B, de las Heras N, Chillón MC, Hernández-Hernández Á, González M, Sánchez-Guijo F, Del Cañizo C.

Leuk Res. 2015 Aug;39(8):921-4. doi: 10.1016/j.leukres.2015.05.014. Epub 2015 Jun 11.

PMID:
26105049
30.

Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome.

Bastida JM, Cabrero M, Lopez-Godino O, Lopez-Parra M, Sanchez-Guijo F, Lopez-Corral L, Vazquez L, Caballero D, Del Cañizo C.

Leuk Res. 2015 Aug;39(8):828-34. doi: 10.1016/j.leukres.2015.05.003. Epub 2015 May 14.

PMID:
26009156
31.

Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant.

Labrador J, López-Corral L, Vazquez L, Sánchez-Guijo F, Guerrero C, Sánchez-Barba M, Lozano FS, Alberca I, Del Cañizo MC, Caballero D, González-Porras JR.

Br J Haematol. 2015 Jun;169(5):719-25. doi: 10.1111/bjh.13344. Epub 2015 Mar 26.

PMID:
25817436
32.

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.

Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, Greil R, Sánchez-Guijo F, Fenaux P; European ALMA Investigators.

Leuk Res. 2015 Mar;39(3):296-306. doi: 10.1016/j.leukres.2014.12.013. Epub 2014 Dec 31.

PMID:
25601157
33.

Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis.

Cabral R, Caballero JC, Alonso S, Dávila J, Cabrero M, Caballero D, Vázquez L, Sánchez-Guijo F, López L, Cañizo MC, Mateos MV, González M.

Hematol Rep. 2014 Nov 19;6(4):5654. doi: 10.4081/hr.2014.5654. eCollection 2014 Nov 19.

34.

[Bone marrow microenvironment in chronic myeloid leukemia: implications for disease physiopathology and response to treatment].

Aristizábal JA, Chandia M, Del Cañizo MC, Sánchez-Guijo F.

Rev Med Chil. 2014 May;142(5):599-605. doi: 10.4067/S0034-98872014000500008. Review. Spanish.

35.

Transcriptomic portrait of human Mesenchymal Stromal/Stem Cells isolated from bone marrow and placenta.

Roson-Burgo B, Sanchez-Guijo F, Del Cañizo C, De Las Rivas J.

BMC Genomics. 2014 Oct 19;15:910. doi: 10.1186/1471-2164-15-910.

36.

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.

Garcia-Gomez A, De Las Rivas J, Ocio EM, Díaz-Rodríguez E, Montero JC, Martín M, Blanco JF, Sanchez-Guijo FM, Pandiella A, San Miguel JF, Garayoa M.

Oncotarget. 2014 Sep 30;5(18):8284-305.

37.

Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

Garcia-Gomez A, Sanchez-Guijo F, Del Cañizo MC, San Miguel JF, Garayoa M.

World J Stem Cells. 2014 Jul 26;6(3):322-43. doi: 10.4252/wjsc.v6.i3.322. Review.

38.

Elderly CML patients' treatment: considering not only physician's judgment but also co-morbidity indexes.

Sánchez-Guijo F.

Leuk Res. 2014 Oct;38(10):1156-7. doi: 10.1016/j.leukres.2014.07.007. Epub 2014 Jul 29. No abstract available.

PMID:
25113280
39.

Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease.

Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parody R, Martínez C, Olavarría E, Andreu E, Prósper F, Díez-Campelo M, Regidor C, Villaron E, López-Corral L, Caballero D, Cañizo MC, Pérez-Simon JA.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1580-5. doi: 10.1016/j.bbmt.2014.06.015. Epub 2014 Jun 19.

40.

NADPH oxidases as therapeutic targets in chronic myelogenous leukemia.

Sánchez-Sánchez B, Gutiérrez-Herrero S, López-Ruano G, Prieto-Bermejo R, Romo-González M, Llanillo M, Pandiella A, Guerrero C, Miguel JF, Sánchez-Guijo F, Del Cañizo C, Hernández-Hernández A.

Clin Cancer Res. 2014 Aug 1;20(15):4014-25. doi: 10.1158/1078-0432.CCR-13-3044. Epub 2014 May 15.

41.

Involvement of primary mesenchymal precursors and hematopoietic bone marrow cells from chronic myeloid leukemia patients by BCR-ABL1 fusion gene.

Chandia M, Sayagués JM, Gutiérrez ML, Chillón ML, Aristizábal JA, Corrales A, Castellanos M, Melón A, Sánchez ML, Bárcena P, Matarraz S, González-González M, Barrena S, López A, Cañizo MC, Sánchez-Guijo F, Orfao A.

Am J Hematol. 2014 Mar;89(3):288-94.

42.

Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome.

Bernal T, Diez-Campelo M, Godoy V, Rojas S, Colado E, Alcoceba M, González M, Vidriales B, Sánchez-Guijo FM, López-Corral L, Luño E, del Cañizo C.

Leuk Res. 2014 May;38(5):551-6. doi: 10.1016/j.leukres.2014.02.001. Epub 2014 Feb 10.

PMID:
24655806
43.

Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.

Labrador J, López-Corral L, López-Godino O, Vázquez L, Cabrero-Calvo M, Pérez-López R, Díez-Campelo M, Sánchez-Guijo F, Pérez-López E, Guerrero C, Alberca I, Del Cañizo MC, Pérez-Simón JA, González-Porras JR, Caballero D.

Bone Marrow Transplant. 2014 May;49(5):684-90. doi: 10.1038/bmt.2014.17. Epub 2014 Feb 24.

44.

Uptake and delivery of antigens by mesenchymal stromal cells.

Sánchez-Abarca LI, Alvarez-Laderas I, Díez Campelo M, Caballero-Velázquez T, Herrero C, Muntión S, Calderón C, García-Guerrero E, Sánchez-Guijo F, Del Cañizo C, San Miguel J, Pérez-Simón JA.

Cytotherapy. 2013 Jun;15(6):673-8. doi: 10.1016/j.jcyt.2013.01.216. Epub 2013 Mar 21.

PMID:
23522868
45.

Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies.

Rocha V, Labopin M, Ruggeri A, Podestà M, Gallamini A, Bonifazi F, Sanchez-Guijo FM, Rovira M, Socie G, Baltadakis I, Michallet M, Deconinck E, Bacigalupo A, Mohty M, Gluckman E, Frassoni F.

Transplantation. 2013 May 27;95(10):1284-91. doi: 10.1097/TP.0b013e318288ca4d.

PMID:
23507699
46.

Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment.

Carrancio S, Romo C, Ramos T, Lopez-Holgado N, Muntion S, Prins HJ, Martens AC, Briñón JG, San Miguel JF, Del Cañizo MC, Sanchez-Guijo F.

Cell Transplant. 2013;22(7):1171-83. doi: 10.3727/096368912X657431. Epub 2012 Oct 2.

47.

Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients.

Labrador J, Lopez-Anglada L, Perez-Lopez E, Lozano FS, Lopez-Corral L, Sanchez-Guijo FM, Vazquez L, Perez Rivera JA, Martin-Herrero F, Sanchez-Barba M, Guerrero C, del Cañizo MC, Caballero MD, San Miguel JF, Alberca I, Gonzalez-Porras JR.

Haematologica. 2013 Mar;98(3):437-43. doi: 10.3324/haematol.2012.069559. Epub 2012 Aug 16.

48.

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.

Garcia-Gomez A, Ocio EM, Crusoe E, Santamaria C, Hernández-Campo P, Blanco JF, Sanchez-Guijo FM, Hernández-Iglesias T, Briñón JG, Fisac-Herrero RM, Lee FY, Pandiella A, San Miguel JF, Garayoa M.

PLoS One. 2012;7(4):e34914. doi: 10.1371/journal.pone.0034914. Epub 2012 Apr 23.

49.

Bone marrow transplantation extends its scope.

Sánchez-Guijo FM, Orfao A, Del Cañizo MC.

Adv Exp Med Biol. 2012;741:121-34. doi: 10.1007/978-1-4614-2098-9_9.

PMID:
22457107
50.

Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients.

Santamaría C, Muntión S, Rosón B, Blanco B, López-Villar O, Carrancio S, Sánchez-Guijo FM, Díez-Campelo M, Alvarez-Fernández S, Sarasquete ME, de las Rivas J, González M, San Miguel JF, Del Cañizo MC.

Haematologica. 2012 Aug;97(8):1218-24. doi: 10.3324/haematol.2011.054437. Epub 2012 Feb 27.

Supplemental Content

Loading ...
Support Center